Related Experiment Videos
Neuroblastoma today
A Ferster1, R Schots, R Maurus
1Oncologie Pédiatrique, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
Abstract:
Notwithstanding the progress made in radiology, nuclear medicine, immunohematology and genetics for more accurate diagnosis and staging in neuroblastoma and the availability of general new efficacious cytostatic drugs, the prognosis of children over 1 yr with advanced disease has remained poor. New refinements in therapeutics with multiagent regimens, massive chemotherapy followed by autologous bone marrow transplantation treatment, with or without immunomagnetic purging, and/or total body irradiation have improved response rate and disease-free survival in metastatic patients, but their effect on long-term survival needs further evaluation.
Insights
Despite advances in diagnosis and treatment, the prognosis for children over one year old with advanced neuroblastoma remains poor. Novel therapeutic strategies show promise in improving response rates and disease-free survival, but long-term outcomes require further study.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Medical Diagnostics
Background:
- Neuroblastoma diagnosis and staging have improved with advances in radiology, nuclear medicine, immunohematology, and genetics.
- Despite new cytostatic drugs, the prognosis for children over one year old with advanced neuroblastoma remains poor.
Purpose of the Study:
- To evaluate the impact of novel therapeutic refinements on neuroblastoma treatment outcomes.
- To assess the effectiveness of multiagent regimens, high-dose chemotherapy, autologous bone marrow transplantation, and total body irradiation in improving patient survival.
Main Methods:
- Review of current therapeutic strategies for advanced neuroblastoma.
- Analysis of treatment outcomes including response rate, disease-free survival, and long-term survival.
- Consideration of adjunct therapies such as immunomagnetic purging and total body irradiation.
Main Results:
- Advanced therapeutic regimens, including high-dose chemotherapy with autologous bone marrow transplantation, have improved response rates and disease-free survival in metastatic neuroblastoma patients.
- The efficacy of these intensive treatments on long-term survival is yet to be fully determined.
Conclusions:
- While current intensive therapies enhance short-term outcomes for advanced neuroblastoma, further research is crucial to establish their long-term survival benefits.
- Continued investigation into novel therapeutic approaches is necessary to improve the overall prognosis for pediatric neuroblastoma patients.